(Q34253418)

English

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models (English)

1 reference

Europe PubMed Central

31 July 2017

lenvatinib mesylate

1 reference

ChEBI release 2020-05-28

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kiyoshi Okamoto

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Yukinori Minoshima

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Osamu Tohyama

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Junji Matsui

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Kotaro Kodama

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Naoko Hata-Sugi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Takayuki Kimura

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Masao Iwata

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Yasuhiro Funahashi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

10 September 2014

1 reference

Europe PubMed Central

31 July 2017

Journal of Thyroid Research

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

638747

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Molecular pathogenesis and mechanisms of thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

New insight into the treatment of advanced differentiated thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Controlling escape from angiogenesis inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Treatment outcome of patients with anaplastic thyroid cancer: a single center experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Cytotoxic chemotherapy for differentiated thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

New therapeutic approaches to treat medullary thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

BRAF mutation in thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Molecular genetics of multiple endocrine neoplasia types 1 and 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Angiogenesis in cancer and other diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphorylation and PDGF-mediated cellular events by a quinoline derivative.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Induction of angiogenesis during the transition from hyperplasia to neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Angiogenic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Point mutations of ras oncogenes are an early event in thyroid tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

6 July 2018

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F638747

21 January 2018

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F638747

21 January 2018

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F638747

21 January 2018

Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F638747

21 January 2018

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177084

28 October 2018

Thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25295214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific pattern of RAS oncogene mutations in follicular thyroid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25295214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25295214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/25295214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25295214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2014/638747

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25295214%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34253418&oldid=1951223917"